Share Price and Basic Stock Data
Last Updated: December 25, 2025, 8:51 am
| PEG Ratio | 1.49 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alpa Laboratories Ltd operates in the pharmaceuticals sector, with a current stock price of ₹78.4 and a market capitalization of ₹165 Cr. The company’s revenue from operations has exhibited fluctuations in recent quarters, with sales recorded at ₹22 Cr in June 2022, rising to ₹32 Cr by September 2023. However, the sales dipped to ₹25 Cr in December 2023 before recovering to ₹39 Cr in March 2025, indicating a volatile revenue trajectory. For the fiscal year ending March 2025, total sales stood at ₹110 Cr, consistent with the trailing twelve months (TTM) figure of ₹110 Cr. The overall sales pattern reflects a strong recovery post-pandemic, although certain quarters such as March 2023 and June 2023 experienced lower sales of ₹93 Cr and ₹25 Cr, respectively. The company’s operational performance, as indicated by the operating profit margin (OPM), has been low, peaking at 32% in March 2023 but averaging around 5% in recent periods, highlighting the need for better cost management and efficiency improvements.
Profitability and Efficiency Metrics
Alpa Laboratories’ profitability metrics indicate a mixed performance. The net profit recorded for the fiscal year ending March 2025 was ₹20 Cr, with an earnings per share (EPS) of ₹9.35, reflecting growth from ₹6.00 in March 2023. Despite these gains, the operating profit margin (OPM) for the same period stood at a mere 5%, a noticeable decline from previous peaks, which suggests challenges in maintaining profitability amid fluctuating sales. Notably, the interest coverage ratio (ICR) reported at 121.23x indicates that the company has ample capacity to meet its interest obligations, as it has no significant debt, with borrowings at just ₹2 Cr. The return on equity (ROE) of 11.5% and return on capital employed (ROCE) of 15% reflect decent operational efficiency compared to industry averages, yet improvements are necessary to enhance shareholder value. Additionally, the cash conversion cycle (CCC) at 150 days points to potential inefficiencies in inventory management and receivables collection that could be targeted for improvement.
Balance Sheet Strength and Financial Ratios
Alpa Laboratories demonstrates a robust balance sheet, with total assets amounting to ₹233 Cr and total liabilities at ₹248 Cr as of March 2025. The reserves have increased significantly to ₹173 Cr, showcasing a solid foundation for future growth and stability. The company’s equity capital remains stable at ₹21 Cr, while long-term debt ratios stand at 0.00, indicating no reliance on external debt for financing operations. The current ratio of 4.12 and quick ratio of 3.74 underline a strong liquidity position, suggesting that the company can easily meet its short-term obligations. However, the price-to-book value (P/BV) ratio of 1.28x suggests that the stock may be slightly overvalued compared to its book value of ₹81.48 per share. The enterprise value (EV) of ₹216.89 Cr, when compared to net operating revenue, reveals an EV/Net Operating Revenue ratio of 1.93, which is relatively high, indicating that the market may be pricing in future growth expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Alpa Laboratories reflects a stable composition, with promoters holding 57.29% of the shares consistently since December 2022. This substantial promoter stake indicates strong management confidence in the company’s future. Institutional investors remain minimal, with Foreign Institutional Investors (FIIs) holding just 0.35% and Domestic Institutional Investors (DIIs) at 0.00%, suggesting limited institutional interest at this stage. Public shareholders constitute 42.36% of the ownership, with the number of shareholders decreasing slightly to 18,542 as of September 2025, indicative of a stable yet cautious investor base. The lack of dividends, as seen in the dividend payout ratio of 0% across recent periods, could deter income-focused investors, although it may be aimed at reinvesting earnings for growth. Overall, the stable promoter holding and lack of significant institutional ownership may suggest both a risk and an opportunity for potential investors, as increased institutional interest could positively impact the stock’s valuation.
Outlook, Risks, and Final Insight
Alpa Laboratories faces both promising opportunities and notable risks as it navigates the competitive pharmaceutical landscape. The potential for revenue growth exists, particularly if the company can enhance its operational efficiencies and improve its OPM, which has been inconsistent. However, risks include the volatility in sales figures, as observed in the recent quarterly trends, and the company’s reliance on a limited product portfolio, which may expose it to market fluctuations. Additionally, the high cash conversion cycle indicates potential inefficiencies that could impact liquidity. On the positive side, the strong financial ratios and absence of debt position the company favorably for future expansion. The outlook remains cautiously optimistic; should Alpa Laboratories effectively leverage its strong balance sheet and operational improvements, it could create substantial shareholder value in the long term. Investors should monitor the execution of strategic initiatives aimed at enhancing profitability and operational efficiency to gauge future performance effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 231/84.3 | 29.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,770 Cr. | 438 | 479/192 | 98.8 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.7 Cr. | 33.3 | 35.0/17.0 | 116 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,181.97 Cr | 1,153.40 | 53.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 14 | 27 | 29 | 25 | 32 | 27 | 24 | 21 | 25 | 26 | 39 | 19 |
| Expenses | 21 | 19 | 25 | 20 | 27 | 29 | 25 | 20 | 21 | 22 | 25 | 39 | 19 |
| Operating Profit | 1 | -6 | 3 | 9 | -1 | 3 | 2 | 4 | 1 | 3 | 1 | -0 | 0 |
| OPM % | 6% | -42% | 10% | 32% | -5% | 10% | 9% | 15% | 3% | 13% | 3% | -1% | 2% |
| Other Income | 2 | 6 | 3 | -1 | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 3 | 12 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 3 | 0 | 5 | 8 | 3 | 6 | 5 | 7 | 5 | 10 | 9 | 2 | 12 |
| Tax % | -0% | -0% | -0% | 42% | -0% | -0% | 15% | 47% | -0% | 20% | -0% | 187% | -0% |
| Net Profit | 3 | 0 | 5 | 5 | 3 | 6 | 5 | 4 | 5 | 8 | 9 | -2 | 12 |
| EPS in Rs | 1.26 | 0.10 | 2.44 | 2.20 | 1.44 | 2.73 | 2.15 | 1.69 | 2.43 | 3.63 | 4.23 | -0.93 | 5.60 |
Last Updated: August 20, 2025, 1:55 pm
Below is a detailed analysis of the quarterly data for Alpa Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 20.00 Cr..
- For Expenses, as of Jun 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 39.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 20.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For OPM %, as of Jun 2025, the value is 2.00%. The value appears strong and on an upward trend. It has increased from -1.00% (Mar 2025) to 2.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 187.00% (Mar 2025) to 0.00%, marking a decrease of 187.00%.
- For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.60. The value appears strong and on an upward trend. It has increased from -0.93 (Mar 2025) to 5.60, marking an increase of 6.53.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 56 | 57 | 53 | 63 | 62 | 77 | 85 | 97 | 112 | 93 | 109 | 110 | 110 |
| Expenses | 51 | 54 | 47 | 56 | 57 | 76 | 79 | 90 | 101 | 85 | 100 | 105 | 112 |
| Operating Profit | 6 | 3 | 7 | 7 | 4 | 1 | 6 | 8 | 11 | 8 | 9 | 5 | -2 |
| OPM % | 10% | 6% | 13% | 11% | 7% | 2% | 7% | 8% | 10% | 9% | 8% | 5% | -2% |
| Other Income | 1 | 2 | 6 | 4 | 5 | 5 | 0 | 4 | 11 | 9 | 14 | 23 | 28 |
| Interest | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Profit before tax | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 | 21 | 26 | 23 |
| Tax % | 4% | -48% | 27% | 34% | 27% | 36% | 20% | 33% | 28% | 21% | 19% | 24% | |
| Net Profit | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 | 17 | 20 | 19 |
| EPS in Rs | -2.45 | -0.67 | 3.68 | 2.85 | 2.27 | 1.40 | 1.94 | 3.45 | 6.72 | 6.00 | 7.98 | 9.35 | 8.95 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 80.00% | 900.00% | -25.00% | -16.67% | -40.00% | 33.33% | 75.00% | 100.00% | -7.14% | 30.77% | 17.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | 820.00% | -925.00% | 8.33% | -23.33% | 73.33% | 41.67% | 25.00% | -107.14% | 37.91% | -13.12% |
Alpa Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 0% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 55% |
| 5 Years: | 30% |
| 3 Years: | 36% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 27% |
| 3 Years: | 15% |
| 1 Year: | -8% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| Last Year: | 11% |
Last Updated: September 4, 2025, 11:00 pm
Balance Sheet
Last Updated: December 10, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 124 | 141 | 161 | 173 |
| Borrowings | 23 | 29 | 24 | 11 | 6 | 2 | 0 | 0 | 6 | 3 | 5 | 0 | 2 |
| Other Liabilities | 15 | 13 | 27 | 20 | 17 | 21 | 21 | 33 | 28 | 30 | 25 | 51 | 52 |
| Total Liabilities | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
| Fixed Assets | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 | 11 | 21 | 21 |
| CWIP | -0 | 0 | -0 | -0 | -0 | 0 | 1 | 2 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 | 109 | 129 | 157 |
| Other Assets | 54 | 113 | 118 | 100 | 79 | 64 | 56 | 80 | 70 | 81 | 72 | 83 | 70 |
| Total Assets | 127 | 128 | 145 | 129 | 127 | 129 | 131 | 150 | 165 | 178 | 192 | 233 | 248 |
Below is a detailed analysis of the balance sheet data for Alpa Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 173.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2025) to 173.00 Cr., marking an increase of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 52.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 248.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 157.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 28.00 Cr..
- For Other Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 13.00 Cr..
- For Total Assets, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 15.00 Cr..
Notably, the Reserves (173.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -26.00 | -17.00 | -4.00 | -2.00 | -1.00 | 6.00 | 8.00 | 5.00 | 5.00 | 4.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 156 | 234 | 169 | 151 | 141 | 105 | 133 | 124 | 186 | 138 | 155 |
| Inventory Days | 148 | 76 | 196 | 131 | 140 | 105 | 90 | 102 | 81 | 84 | 73 | 92 |
| Days Payable | 121 | 91 | 244 | 140 | 130 | 99 | 98 | 152 | 78 | 100 | 63 | 97 |
| Cash Conversion Cycle | 157 | 141 | 187 | 160 | 161 | 148 | 97 | 83 | 127 | 170 | 149 | 150 |
| Working Capital Days | 65 | -4 | 224 | 197 | 204 | 189 | 121 | 137 | 124 | 150 | 132 | 108 |
| ROCE % | -3% | 0% | 10% | 11% | 7% | 4% | 7% | 7% | 9% | 11% | 14% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Diluted EPS (Rs.) | 9.34 | 8.01 | 5.88 | 6.70 | 3.44 |
| Cash EPS (Rs.) | 10.32 | 8.90 | 6.61 | 7.48 | 4.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 81.48 | 72.20 | 63.96 | 57.85 | 51.16 |
| Revenue From Operations / Share (Rs.) | 53.45 | 51.68 | 44.18 | 53.36 | 46.36 |
| PBDIT / Share (Rs.) | 13.36 | 10.93 | 8.29 | 10.19 | 5.75 |
| PBIT / Share (Rs.) | 12.31 | 10.00 | 7.66 | 9.40 | 5.16 |
| PBT / Share (Rs.) | 12.20 | 9.83 | 7.55 | 9.30 | 5.13 |
| Net Profit / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| NP After MI And SOA / Share (Rs.) | 9.27 | 7.97 | 5.98 | 6.70 | 3.44 |
| PBDIT Margin (%) | 24.98 | 21.14 | 18.76 | 19.09 | 12.39 |
| PBIT Margin (%) | 23.03 | 19.35 | 17.33 | 17.61 | 11.13 |
| PBT Margin (%) | 22.82 | 19.01 | 17.09 | 17.42 | 11.05 |
| Net Profit Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| NP After MI And SOA Margin (%) | 17.34 | 15.42 | 13.53 | 12.55 | 7.42 |
| Return on Networth / Equity (%) | 11.37 | 11.04 | 9.34 | 11.57 | 6.73 |
| Return on Capital Employeed (%) | 14.72 | 13.63 | 11.90 | 15.97 | 10.07 |
| Return On Assets (%) | 8.76 | 9.19 | 7.52 | 9.07 | 5.16 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.03 | 0.01 | 0.04 | 0.00 |
| Asset Turnover Ratio (%) | 0.55 | 0.62 | 0.57 | 0.73 | 0.71 |
| Current Ratio (X) | 4.12 | 5.74 | 4.67 | 4.43 | 3.73 |
| Quick Ratio (X) | 3.74 | 5.25 | 4.28 | 3.93 | 3.22 |
| Inventory Turnover Ratio (X) | 7.18 | 8.27 | 3.73 | 3.96 | 3.73 |
| Interest Coverage Ratio (X) | 121.23 | 64.02 | 78.01 | 97.84 | 155.24 |
| Interest Coverage Ratio (Post Tax) (X) | 85.14 | 47.71 | 57.27 | 65.32 | 94.03 |
| Enterprise Value (Cr.) | 216.89 | 179.04 | 106.65 | 149.57 | 65.56 |
| EV / Net Operating Revenue (X) | 1.93 | 1.65 | 1.15 | 1.33 | 0.67 |
| EV / EBITDA (X) | 7.72 | 7.79 | 6.11 | 6.98 | 5.42 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| Price / BV (X) | 1.28 | 1.16 | 0.84 | 1.20 | 0.70 |
| Price / Net Operating Revenue (X) | 1.95 | 1.61 | 1.22 | 1.30 | 0.77 |
| EarningsYield | 0.08 | 0.09 | 0.11 | 0.09 | 0.09 |
After reviewing the key financial ratios for Alpa Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.34. This value is within the healthy range. It has increased from 8.01 (Mar 24) to 9.34, marking an increase of 1.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.32. This value is within the healthy range. It has increased from 8.90 (Mar 24) to 10.32, marking an increase of 1.42.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.48. It has increased from 72.20 (Mar 24) to 81.48, marking an increase of 9.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 53.45. It has increased from 51.68 (Mar 24) to 53.45, marking an increase of 1.77.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.36. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 13.36, marking an increase of 2.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.31. This value is within the healthy range. It has increased from 10.00 (Mar 24) to 12.31, marking an increase of 2.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.20. This value is within the healthy range. It has increased from 9.83 (Mar 24) to 12.20, marking an increase of 2.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.27. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 9.27, marking an increase of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 24.98. This value is within the healthy range. It has increased from 21.14 (Mar 24) to 24.98, marking an increase of 3.84.
- For PBIT Margin (%), as of Mar 25, the value is 23.03. This value exceeds the healthy maximum of 20. It has increased from 19.35 (Mar 24) to 23.03, marking an increase of 3.68.
- For PBT Margin (%), as of Mar 25, the value is 22.82. This value is within the healthy range. It has increased from 19.01 (Mar 24) to 22.82, marking an increase of 3.81.
- For Net Profit Margin (%), as of Mar 25, the value is 17.34. This value exceeds the healthy maximum of 10. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.34. This value is within the healthy range. It has increased from 15.42 (Mar 24) to 17.34, marking an increase of 1.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.37. This value is below the healthy minimum of 15. It has increased from 11.04 (Mar 24) to 11.37, marking an increase of 0.33.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.72. This value is within the healthy range. It has increased from 13.63 (Mar 24) to 14.72, marking an increase of 1.09.
- For Return On Assets (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 8.76, marking a decrease of 0.43.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.55. It has decreased from 0.62 (Mar 24) to 0.55, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has decreased from 5.74 (Mar 24) to 4.12, marking a decrease of 1.62.
- For Quick Ratio (X), as of Mar 25, the value is 3.74. This value exceeds the healthy maximum of 2. It has decreased from 5.25 (Mar 24) to 3.74, marking a decrease of 1.51.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.18. This value is within the healthy range. It has decreased from 8.27 (Mar 24) to 7.18, marking a decrease of 1.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 121.23. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 121.23, marking an increase of 57.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 85.14. This value is within the healthy range. It has increased from 47.71 (Mar 24) to 85.14, marking an increase of 37.43.
- For Enterprise Value (Cr.), as of Mar 25, the value is 216.89. It has increased from 179.04 (Mar 24) to 216.89, marking an increase of 37.85.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 1.93, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 7.79 (Mar 24) to 7.72, marking a decrease of 0.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For Price / BV (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 1.28, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 1.95, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 24) to 0.08, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alpa Laboratories Ltd:
- Net Profit Margin: 17.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.72% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.37% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 85.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 8.76 (Industry average Stock P/E: 53.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 33/2, Pigdamber, A.B.Road, Rau, Indore Madhya Pradesh 453446 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra Singh Chawla | Chairman |
| Mr. Paresh Chawla | Managing Director |
| Mr. Pravin Shah | Director |
| Mr. Vitthal Kothana | Director |
| Mr. Shitul Shah | Director |
| Mrs. Jyoti Jain | Independent Director |
| Mr. Sanket Baheti | Independent Director |
| Mr. Pratik Shah | Independent Director |
| Mrs. Pratibha Lunawat | Independent Director |
| Mr. Sunil Kumar Valecha | Independent Director |
FAQ
What is the intrinsic value of Alpa Laboratories Ltd?
Alpa Laboratories Ltd's intrinsic value (as of 25 December 2025) is 75.63 which is 3.53% lower the current market price of 78.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 165 Cr. market cap, FY2025-2026 high/low of 137/75.0, reserves of ₹173 Cr, and liabilities of 248 Cr.
What is the Market Cap of Alpa Laboratories Ltd?
The Market Cap of Alpa Laboratories Ltd is 165 Cr..
What is the current Stock Price of Alpa Laboratories Ltd as on 25 December 2025?
The current stock price of Alpa Laboratories Ltd as on 25 December 2025 is 78.4.
What is the High / Low of Alpa Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alpa Laboratories Ltd stocks is 137/75.0.
What is the Stock P/E of Alpa Laboratories Ltd?
The Stock P/E of Alpa Laboratories Ltd is 8.76.
What is the Book Value of Alpa Laboratories Ltd?
The Book Value of Alpa Laboratories Ltd is 92.0.
What is the Dividend Yield of Alpa Laboratories Ltd?
The Dividend Yield of Alpa Laboratories Ltd is 0.00 %.
What is the ROCE of Alpa Laboratories Ltd?
The ROCE of Alpa Laboratories Ltd is 15.0 %.
What is the ROE of Alpa Laboratories Ltd?
The ROE of Alpa Laboratories Ltd is 11.5 %.
What is the Face Value of Alpa Laboratories Ltd?
The Face Value of Alpa Laboratories Ltd is 10.0.